Sign in
Active, not recruitingNo phase

Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study

Key facts

Who runs it
Bluejay Diagnostics, Inc.
Where
Boston, Gainesville, Nashville, Salt Lake City, and Winston-Salem, United StatesSee the 5 sites
Trial code
Status
Active, not recruiting
People taking part
700 people, planned
Started
12 Nov 2024
Expected to end
31 Dec 2026
Type of study
Observational
Record updated
1 October 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult patients (≥22 years of age)
  • Diagnosis of sepsis or septic shock based on: the Third International Consensus Definitions (Sepsis-3 criteria) defined as at least one of the following criteria as determined by a treating physician or study physician investigator; Sepsis: suspected or documented infection (i.e., use or intent to use antibiotics as an indicator) and organ dysfunction defined by a Sequential Organ Failure Assessment (SOFA) score ≥2; Septic shock: sepsis requiring vasopressors and serum lactate levels >2 mmol/L (18 mg/dL)
  • Admitted or intended to be admitted to the ICU
  • At least 3 mL plasma drawn and available for collection (or is anticipated to be able to be drawn and available) within 24 hours of (i.e., up to 24 hours after) the earliest diagnosis of sepsis or septic shock

Who cannot take part

  • Prior enrollment into this study
  • Prisoners or imprisonment at time of enrollment
  • Informed consent as approved by IRB is unable to be obtained

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United States
  • University of Florida College of MedicineGainesville, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Intermountain HealthSalt Lake City, United States
  • Wake Forest School of MedicineWinston-Salem, United States

About the trial

What the trial wants to find out

The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
1 October 2026